尔康制药
(300267)
| 流通市值：45.80亿 | | | 总市值：66.42亿 |
| 流通股本：14.22亿 | | | 总股本：20.63亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 567,555,422.78 | 247,387,142.02 | 1,165,761,300.56 | 1,006,423,651.81 |
| 营业收入 | 567,555,422.78 | 247,387,142.02 | 1,165,761,300.56 | 1,006,423,651.81 |
| 二、营业总成本 | 531,027,229.43 | 241,298,499.46 | 1,164,383,715.31 | 985,154,942.51 |
| 营业成本 | 389,552,075.9 | 177,065,791.22 | 857,491,399.96 | 730,971,679.11 |
| 税金及附加 | 7,502,398.08 | 4,216,487.11 | 14,362,107.16 | 10,769,674.33 |
| 销售费用 | 31,347,083.78 | 12,997,017.35 | 59,758,166.4 | 42,686,764.62 |
| 管理费用 | 81,658,137.36 | 38,638,919.77 | 185,223,159.81 | 166,946,302.81 |
| 研发费用 | 22,604,241.94 | 9,028,182.72 | 45,073,664.26 | 30,243,874.28 |
| 财务费用 | -1,636,707.63 | -647,898.71 | 2,475,217.72 | 3,536,647.36 |
| 其中:利息费用 | 5,513,309.51 | 2,403,625.66 | 9,667,180.03 | 8,500,831.33 |
| 其中:利息收入 | 3,022,749.11 | 1,499,426.57 | 5,920,678.43 | 4,259,238.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -3,434,475.86 | -4,450,541.22 |
| 加:投资收益 | 300,898.51 | 280,508.39 | -18,168,794.63 | 3,493,479.34 |
| 资产处置收益 | -278,275.91 | 31,037.09 | 313,748.98 | 329,127.92 |
| 资产减值损失(新) | -2,520,227.58 | 222,734.62 | -358,230,770.03 | -1,044,096.3 |
| 信用减值损失(新) | -293,516.76 | -665,751.92 | 1,248,626.86 | 3,986,929.68 |
| 其他收益 | 6,144,292.12 | 4,302,303.55 | 11,859,340.41 | 10,685,366.8 |
| 四、营业利润 | 39,881,363.73 | 10,259,474.29 | -365,034,739.02 | 34,268,975.52 |
| 加:营业外收入 | 818,359.08 | 29,044.38 | 3,037,605.34 | 941,328.18 |
| 减:营业外支出 | 166,153.21 | 49,993.13 | 5,818,925.1 | 4,460,141.02 |
| 五、利润总额 | 40,533,569.6 | 10,238,525.54 | -367,816,058.78 | 30,750,162.68 |
| 减:所得税费用 | 6,646,279.69 | 807,305.44 | 31,495,201.13 | 3,639,448.23 |
| 六、净利润 | 33,887,289.91 | 9,431,220.1 | -399,311,259.91 | 27,110,714.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,887,289.91 | 9,431,220.1 | -399,311,259.91 | 27,110,714.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 44,469,036.25 | 13,108,583.76 | -379,817,624.23 | 39,575,891.64 |
| 少数股东损益 | -10,581,746.34 | -3,677,363.66 | -19,493,635.68 | -12,465,177.19 |
| 扣除非经常损益后的净利润 | 41,189,712.69 | 10,963,027.66 | -385,813,037.2 | 35,230,318.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.01 | -0.18 | 0.02 |
| (二)稀释每股收益 | 0.02 | 0.01 | -0.18 | 0.02 |
| 八、其他综合收益 | -55,824,276.59 | -25,060,678.8 | -33,376,075.86 | -17,720,724.55 |
| 归属于母公司股东的其他综合收益 | -56,453,149.97 | -25,364,172.52 | -33,713,295.78 | -17,860,457.67 |
| 九、综合收益总额 | -21,936,986.68 | -15,629,458.7 | -432,687,335.77 | 9,389,989.9 |
| 归属于母公司股东的综合收益总额 | -11,984,113.72 | -12,255,588.76 | -413,530,920.01 | 21,715,433.97 |
| 归属于少数股东的综合收益总额 | -9,952,872.96 | -3,373,869.94 | -19,156,415.76 | -12,325,444.07 |
| 公告日期 | 2026-08-27 | 2026-04-24 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |